Anti‐CD19 chimeric antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia: An open‐label pragmatic clinical trial-Reference-Cited by-同舟云学术

Anti‐CD19 chimeric antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia: An open‐label pragmatic clinical trial

Published:2019-08-02 Issue:10 Volume:94 Page:1113-1122
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Jiang Huiwen¹²^ORCID,Li Chenggong¹²,Yin Ping³,Guo Tao¹²,Liu Lin¹,Xia Linghui¹,Wu Yaohui¹²,Zhou Fen¹⁴,Ai Lisha¹,Shi Wei¹,Lu Xuan¹,Wang Huafang¹,Tang Lu¹²,Wei Qiuzhe¹,Deng Jun¹²,Jin Runming¹⁴,Xiong Wei²,Dong Jian²,Mei Heng¹²^ORCID,Hu Yu¹²^ORCID

Affiliation:

1. Institute of Hematology, Union Hospital, Tongji Medical CollegeHuazhong University of Science and Technology Wuhan 430022 China.

2. Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease Wuhan 430022 China.

3. Department of Epidemiology and BiostatisticsSchool of Public Health, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430030 China.

4. Department of PediatricsUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan 430022 China.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25582

Reference45 articles.

1. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

2. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation